Working Group of Gyneacological Oncology and Breast Healthcare
Groupe de travail pour l’oncologie gynécologique et de la santé du sein
Swiss Society for Gynaecology and Obstetrics SGGG
Société suisse de gynécologie et d’obstétrique
Created: 27. Januar 1997
Last revision: 24. Juli 2008
1. Name, seat and purpose of the Working Group (hereinafter referred to as AGO)
§ 1 Name: Working Group Gynaecological Oncology and Breast Healthcare -
is an association within the SGGG (Swiss Society for Gynaecology and Obstetrics). The AGO’s dual affiliation is conveyed in written communication by the name Working Group Gynaecological Oncology and Breast Health of the Swiss Society for Gynaecology and Obstetrics (SGGG).
The seat of the AGO coincides with the seat of the SGGG.
- 2 Purpose and Objective
Within the framework of the tasks performed by the Swiss Society for Gynaecology and Obstetrics, the AGO deals most specifically with the clinical, scientific and organisational concerns of gynaecological oncology, including breast health. It champions these concerns at the meetings of the Swiss Society for Gynaecology and Obstetrics, as well as the Swiss Working Group for Clinical Cancer Research (SAKK). The AGO pursues exclusively activities of public interest.
In addition to the above, the AGO has the following objectives:
- Establishing diagnostic and therapeutic guidelines
- Organising scientific conferences, workshops and courses
- Cooperating with AGO in Germany, Austria and other countries
- Coordinating and cooperating in the field of scientific studies with the Swiss Working Group for Clinical Cancer Research (SAKK).
- Determining suitable training venues for Gynaecological Oncology within the framework of continuing education in Gynaecology and Obstetrics
- Determining of the professional requirements for the FMH- specialist medical title “core area gynaecological oncology”.
2. Organisation of the Working Group Gynaecological Oncology and
§ 3 Full members, associate members, free members, corresponding members, honorary members
- Full members:
The status of full member of the AGO can only be granted to members of the SGGG, or of another recognised Swiss Society, as long as they are still actively engaged in their professional careers.
- Associate members:
The status of associate member can be granted to all doctors or academics who are interested in the objectives of the AGO.
- Free members:
All full and associate members who have reached the age of 70, on the basis of a communication to this effect, can be granted the status of free members by the executive board. Based on a substantiated request, free membership can be granted to other members. Free members maintain their existing rights. They are exempted from annual contributions.
- Corresponding members:
Members of a Working Group Gynaecological Oncology abroad.
- Honorary members:
Members who have been granted this status by the executive board.
- Members of the AGO are all attendees of the foundation meeting, as well as persons designated to this purpose.
§ 4 Membership application
Requests for membership must include all relevant data on the applicant’s professional career, activity and publications in the field of oncology, and be sent to the attention of the President of the AGO. Prerequisite for membership is a particular interest in Gynaecological Oncology and Breast Health. Acceptance is granted by the executive board.
§ 5 Membership expires
- upon withdrawal from the AGO
- upon exclusion for important reasons from the SGGG
- through loss of membership in the Association of Swiss Doctors (FMH)
b) Funds of the Working Group Gynaecological Oncology and
§ 6 Finances
The AGO is financially independent from the SGGG. Membership fees are determined by the general meeting. The AGO can be supported by contributions from sponsors. The financial resources of the AGO are managed by the first deputy chairman. The first deputy chairman presents the budget at the general meeting on a yearly basis.
In its quality as affiliate of the SGGG, the AGO commits to share its annual accounts with the treasurer of the SGGG, without being requested to do so and on a yearly basis. The SGGG takes care of taxation, settling accounts with the AGO.
c) Bodies and Activities of the Working Group Gynaecological
Oncology and Breast Health
§ 7 Bodies
The bodies of the AGO are as follows:
- The general meeting
- The executive board
- The supervisory authority (auditors)
§ 8 General meeting
The regular general meeting normally takes place during the annual general meeting of the SGGG. Handling of matters during the regular general meeting pertains to the Working Group Gyneacological Oncology and Breast Health, along with elections, voting and scientific activities. However, the above is subject to coordination with the executive board of the SGGG. At the general meeting at least the activities carried out by the AGO during the past year, in addition to potential future projects and other subjects, will be discussed. Moreover, at the general meeting deliberated decisions on changes in the executive board, as well as reports on new admissions to the AGO will be taken. Conferences aim to approach a specific topic in Gyneacological Oncology and Breast Healthcare in a comprehensive manner, to up-date attendees on the current state of knowledge. These may include joint scientific conferences with the Working Group Gyneacological Oncology and Breast Healthcare of the Austrian Society for Gynecology and Obstetrics or with the German Society for Gynecology and Obstetrics. As a rule, each university clinic is responsible for the organization of such an event, by rotation, on a yearly basis.
§ 9 Executive Board
Voting within the general meeting takes place by its members on the bases of the simple majority of the members present. The executive board must represent the following departments: Breast healthcare/senology, education / professional development, research, public relations/web site.
The board and the extended executive board will be elected.
The board remains in office for 3 years; board members can be re-elected.
The board shall comprise of at least 6 representatives from the area of clinical gynecology and includes the following positions:
- The first chair (actual president).
- The past president.
- The first deputy chair.
- At least one person responsible for breast healthcare/senology (dual function possible)
- At least one person responsible for continuing education/professional development (dual function possible).
- At least one person responsible for research (dual function possible). Should the Breast Cancer Care of the SAKK be co-presided by a gyneacologist, the latter shall hold a seat in the board.
- At least one person responsible for public relations/web site (dual function possible).
The extended board shall include:
- A representative from medical oncology.
- A representative from gyneacological radiotherapy.
- A representative from gyneacological pathology.
- A representative from gyneacological cytology.
The board shall elect a president from amongst its members.
Additionally, a first deputy chair shall be elected.
- Duties of the president and his deputy
Their duties shall include:
- The preparation of the planning identified according to the core functions of the AGO, that shall build the subject of discussion and decision by the board.
- External representation of the AGO, as long as this task is not performed by the SGGG.
- Ad-hoc decisions on specific questions requiring formulation of an urgent opinion will be made jointly with pre-selected experts of the SGGG and on behalf of the SGGG.
- Regular reporting on the activities of the AGO to the Swiss Society for gyneacology and Obstetrics.
- Covering additional or combined functions within the AGO and SGGG is allowed.
- Duties of the executive board
- Decision-making concerning joint individuation of the core functions of the AGO.
- Responsibility for publishing recommendations, issued on behalf of the AGO.
- Decision-making concerning the scientific program of the conferences of the AGO.
- Vetting applications for membership and deciding on acceptance or exclusion.
- The executive board handles all matters relating to the Working Gyneacological Oncology and Breast Health, as long as these are not transferred to another body.
External representation can only be undertaken in consultation with and with the consent of the SGGG. Professional policies, professional questions, information policy etc. of general Swiss interest, relations with the FMH board, and relations with national and foreign authorities will exclusively be reserved for the SGGG board.
One member of the AGO board will be delegated to the SGGG advisory board to represent the AGO’s interest within the SGGG advisory board. Usually, this delegate is the president of the AGO.
The board member responsible for breast healthcare within the AGO board, should have proven merits and an established network in the field of breast healthcare/senology.
d) Publication media and scientific events
§ 10 Publications and events
- Provision is made for independent workshops and training sessions of the AGO. These can be organized jointly with other working communities or groups.
-The chairperson shall informally send newsletters to the members conveying relevant information of the work of the AGO, or its members.
- Information, explanations or recommendations of the AGO to be shared with all the gyneacologists of the SGGG, and on whose contents a decision is made by the board, are published in the information bulletin of the SGGG, upon approval by the SGGG board.
3. Changes to the statutes
§ 11 Amendment of the statutes
Changes to the rules of procedure require the approval by the general meeting on the basis of a simple majority of the members present. For this purpose, the consent of the SGGG is required.
4. Power to sign
§ 12 Power to sign
Any two members of the restricted board shall have the authority to sign.
5. Dissolution of the Working Group Gynaecological Oncology and Breast Health
§ 13 Dissolution
Dissolution of the AGO can occur based on a decision taken by the general meeting, a judge or by law. The decision requires a majority of two thirds of active members. The assets of the AGO shall be transferred to the SGGG as special assets.
For the board of directors Prof. Dr. med. Daniel Fink